Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings

Renée Hangaard Olesen, Nicholas Carlson, Jens Søndergaard, Ellen Linnea Freese Ballegaard, Rikke Borg, Lars Holger Ehlers

Open source

DOI
10.1016/j.xkme.2026.101363
Published
2026-06
Container
Kidney Medicine
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.xkme.2026.101363,
  title = {Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings},
  author = {Renée Hangaard Olesen and Nicholas Carlson and Jens Søndergaard and Ellen Linnea Freese Ballegaard and Rikke Borg and Lars Holger Ehlers},
  year = {2026},
  journal = {Kidney Medicine},
  doi = {10.1016/j.xkme.2026.101363},
  url = {https://doi.org/10.1016/j.xkme.2026.101363}
}

RIS

TY  - JOUR
TI  - Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings
AU  - Renée Hangaard Olesen
AU  - Nicholas Carlson
AU  - Jens Søndergaard
AU  - Ellen Linnea Freese Ballegaard
AU  - Rikke Borg
AU  - Lars Holger Ehlers
PY  - 2026
JO  - Kidney Medicine
DO  - 10.1016/j.xkme.2026.101363
UR  - https://doi.org/10.1016/j.xkme.2026.101363
ER  - 

APA

Olesen, R. H., Carlson, N., Søndergaard, J., Ballegaard, E. L. F., Borg, R., & Ehlers, L. H. (2026). Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings. Kidney Medicine. https://doi.org/10.1016/j.xkme.2026.101363

Source records